SMARTEST
SMARTEST is a randomised controlled trial to understand how to best treat early-stage type 2 diabetes pharmacologically.
Details
- Period: 2019-06-01 – 2026-12-31
The SMARTEST study logo.
Project description
SMARTEST is a multicentre, open-label, blinded endpoint, randomized controlled trial to compare the SGLT-2 inhibitor dapagliflozin with metformin as first-line treatment for early-stage type 2 diabetes with respect to occurrence of macrovascular and microvascular events and mortality as well as risk markers for comorbidities, safety, quality-of-life, and healthcare costs.
2050 subjects have been enrolled at around 40 local study sites (mainly primary health care centres) and randomized 1-to-1 to receive either metformin 1000-3000 mg/day or dapagliflozin 10 mg/day in monotherapy. The follow-up will be performed in a real-world setting, mainly within regular health care, and endpoints will be collected via national health care registers. The study is coordinated by Uppsala University (sponsor) and Uppsala University Hospital.
Chosen publications
Sundström J, Kristófi R, Östlund O, Bennet L, Eliasson B, Jansson S, Leksell J, Almby K, Lundqvist M, Eriksson JW; SMARTEST study group. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications 2021 35:107996